Factors Associated with New-Onset Atrial Fibrillation in Thai Adults with Hypertension
Issued Date
2025-12-01
Resource Type
ISSN
08957061
eISSN
19417225
Scopus ID
2-s2.0-105021860209
Pubmed ID
40796195
Journal Title
American Journal of Hypertension
Volume
38
Issue
12
Start Page
1076
End Page
1087
Rights Holder(s)
SCOPUS
Bibliographic Citation
American Journal of Hypertension Vol.38 No.12 (2025) , 1076-1087
Suggested Citation
Limpijankit V., Sasiprapha T., Teza H., Pattanateepapon A., Siriyotha S., Boonmanunt S., Attia J., Thakkinstian A. Factors Associated with New-Onset Atrial Fibrillation in Thai Adults with Hypertension. American Journal of Hypertension Vol.38 No.12 (2025) , 1076-1087. 1087. doi:10.1093/ajh/hpaf149 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/113173
Title
Factors Associated with New-Onset Atrial Fibrillation in Thai Adults with Hypertension
Corresponding Author(s)
Other Contributor(s)
Abstract
BACKGROUND Data on risk factors for new-onset atrial fibrillation (NOAF) in hypertensive Asian populations are limited. This study aimed to identify predictors of NOAF in Thai adults with hypertension (HTN). METHODS We conducted a retrospective cohort study of adults (≥18 years) newly diagnosed with HTN at Ramathibodi Hospital, Bangkok, from 2010 to 2023. Patients with prior AF or predisposing conditions (e.g., valvular disease and hyperthyroidism) were excluded. Baseline demographics, comorbidities, and medication use were analyzed as time-varying covariates using multivariable Cox models. RESULTS Of 293,798 hypertensive patients, 168,441 met the criteria. Over a median follow-up of 3.7 years, 5,028 developed NOAF (5.7 per 1,000 person-years). A significant interaction between age and body mass index (BMI) was observed. In patients <60 years, low BMI increased NOAF risk (HR: 2.3; 95% CI: 1.4-3.6), while overweight and obesity did not. In those ≥60-79 years, NOAF risk increased 2- to 3-fold in underweight, overweight, and obese individuals compared to normal BMI. In patients ≥80 years, the risk was 3- to 4-fold higher across all BMI categories. Male sex and comorbidities (vascular disease, stroke, heart failure, chronic kidney disease, and hyperuricemia) were associated with a 1.2-1.8-fold increased risk. Statin use reduced NOAF risk (HR: 0.8; 95% CI: 0.7-0.9), while SGLT2 inhibitors and GLP-1 receptor agonists showed a non-significant protective trend (HR: 0.8; 95% CI: 0.7-1.1). CONCLUSIONS In Thai hypertensive patients, older age, male sex, abnormal BMI, and comorbidities predict NOAF, while statin use may be protective. Further prospective studies are needed to confirm these findings.